849235-61-6 Usage
General Description
4-[(5-BROMOPYRIMIDIN-2-YL)THIO]ANILINE is a chemical compound with the molecular formula C9H7BrN4S. It is a derivative of aniline, containing a thioether group and a bromopyrimidine moiety. 4-[(5-BROMOPYRIMIDIN-2-YL)THIO]ANILINE has potential applications in pharmaceutical and agrochemical industries. The bromopyrimidine group makes it a valuable building block for the synthesis of biologically active molecules, while the thioether functionality can impart specific properties to the resulting compounds. Its structure and properties make it a versatile intermediate for the synthesis of various chemicals with potential biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 849235-61-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,2,3 and 5 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 849235-61:
(8*8)+(7*4)+(6*9)+(5*2)+(4*3)+(3*5)+(2*6)+(1*1)=196
196 % 10 = 6
So 849235-61-6 is a valid CAS Registry Number.
849235-61-6Relevant articles and documents
Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity
Moradei, Oscar M.,Mallais, Tammy C.,Frechette, Sylvie,Paquin, Isabelle,Tessier, Pierre E.,Leit, Silvana M.,Fournel, Marielle,Bonfils, Claire,Trachy-Bourget, Marie-Claude,Liu, Jianhong,Yan, Theresa P.,Lu, Ai-Hua,Rahil, Jubrail,Wang, James,Lefebvre, Sylvain,Li, Zuomei,Vaisburg, Arkadii F.,Besterman, Jeffrey M.
, p. 5543 - 5546 (2008/03/27)
Significant effort is being made to understand the role of HDAC isotypes in human cancer and to develop antitumor agents with better therapeutic windows. A part of this endeavor was the exploration of the 14 ? internal cavity adjacent to the enzyme catalytic site, which led to the design and synthesis of compound 4 with the unusual bis-(aryl)-type pharmacophore. SAR studies around this lead resulted in optimization to potent, selective, nonhydroxamic acid HDAC inhibitors.
